Patients with COVID-19 are treated with the antiviral drug molnupiravir, which is in phase III trials. It is an isopropyl ester prodrug that the host's esterases in the plasma transform into the active nucleoside analogue D-N4-hydroxycytidine (NHC). Positive- and negative-sense RNA viruses are both susceptible to NHC's antiviral action. The creation of Molnupiravir for the treatment of influenza and coronavirus infections has been the focus of recent study. Molnupiravir is a pyrimidine ribonucleoside analogue which has a chemical name of ((2R, 3S, 4R, 5R)-3, 4- dihydroxy-5-(4-(hydroxyamino)-2-oxopyrimidin-1-(2H)-yl)-tetrahydrofuran-2-yl)methyl isobutyrate.